Dry eye is a chronic and progressive disease that negatively impacts our patients’ quality of life and limits the visual treatments we prescribe.
Doctors and patients are often frustrated with the involved and complex treatment of this disease.
Dry eye is a multifactorial disease that has no cure, and the average patient requires multiple treatments. Many patients require numerous therapies such as lid hygiene, heat masks, thermal pulsation, topical anti-inflammatories, amniotic membranes, punctal occlusion and many other FDA and non-FDA approved treatments to decrease patient symptoms.
For years, doctors and patients have desired new treatment options for dry eye.
Optometry and ophthalmology are disciplines that have embraced new technology better than any other medical specialty and finally, the time for new remedies have come.
Allergan received FDA approval of its novel neurostimulation device for the treatment of dry eye on April 25, 2017.
TrueTear was invented by a team of experts at Stanford led by Dr. Michael Ackermann, a PhD in neurostimulation.
The device was further developed in Silicone Valley, home to the world’s most innovative and disruptive technologies.
This singular technology creates an entirely new treatment class in eye care representing a true paradigm shift in the treatment of dry eye.
This produces true tears, containing meibum from the meibomian glands, aqueous from the lacrimal glands and mucin from goblet cell degranulation.
For decades, patients and doctors have struggled with dry eye, and both have always desired new and more efficacious treatment options.
This device offers you and your patients a new, innovative treatment option.